BMY Bristol-Myers Squibb Company
USHealthcareAs of 2026-08-24
Why BMY matters now
Bristol-Myers Squibb Company (BMY) is a US stock in Healthcare. The latest InvestLog snapshot shows $67.29 with +0.42% on the session and $137.45B in market capitalization; recent performance reads 1-month -7.39% and YTD +0.11%.
The latest financial table shown here is Q1 2026, with revenue of $11.49B, net income of $2.68B, and EPS of $1.31. Investors can compare that operating picture with valuation signals such as P/E 16.93 and FCF yield 10.8%.
InvestLog's latest related AI research is a Earnings Analysis note titled "BMY earnings call: guidance, demand, margins, analyst Q&A". The latest indexable market news headline is "JP Morgan Warns of Fall Sell-Off Potential: 5 Defensive Dividend Stocks to Buy" from 247 Wallst.
Additional event context on this page matters because analyst consensus is Hold with a median target of $60.00; recent insider activity includes Haller Julia A filing M-Exempt; recent congressional disclosure data includes Mike Kelly Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
16.93
PEG
0.09
P/B
5.50
P/S
2.27
EV/EBITDA
10.56
DCF Value
$274.02
FCF Yield
10.8%
Div Yield
4.6%
Margins & Returns
Gross Margin
68.7%
Operating Margin
25.7%
Net Margin
15.0%
ROE
39.0%
ROA
8.4%
ROIC
13.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $11.49B | $2.68B | $1.31 |
| Q4 2025 | $12.50B | $1.09B | $0.53 |
| FY 2025 | $48.19B | $7.05B | $3.45 |
| Q3 2025 | $12.22B | $2.20B | $1.08 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$62.60
Target (Median)
$60.00
Target Range
$40.00 - $75.00
Trading Activity
Insider Trades
Congress Trades
Related AI Research
BMY earnings call: guidance, demand, margins, analyst Q&A百时美施贵宝 (BMY) 电话会要点:指引、需求、利润率、分析师问答
David Elkins: We are increasing our full year 2026 financial guidance for both revenue and adjusted diluted EPS based upon our strong first half results and our current projections for the balance of the year, while maintaining our projections for gross margin, other income and expense and our tax rate.大卫·埃尔金斯:基于强劲的上半年业绩以及对下半年的当前预测,我们上调2026年全年营收和调整后摊薄每股收益的财务指引,同时维持对毛利率、其他收支及税率的预测。
BMY earnings release — EPS beat +27.5% · revenue beat +10.5%百时美施贵宝 (BMY) 财报发布 — EPS 高于预期+27.5% · 营收 高于预期+10.5%
Bristol-Myers Squibb Company reported EPS $2.04 vs $1.60 estimate and revenue $13.0B vs $11.7B estimate.百时美施贵宝 公布财报:EPS $2.04 vs $1.60 预期,营收 $13.0B vs $11.7B 预期。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US
Exchange
—
Beta
0.24
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.